nevirapine has been researched along with Hepatitis in 6 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
Hepatitis: INFLAMMATION of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report a case in which an HIV-positive man developed general malaise, skin rash and biochemical hepatitis within days of starting a nevirapine-based antiretroviral treatment regimen." | 7.80 | Rash and hepatitis within days of starting a new antiretroviral regimen: nevirapine hypersensitivity, secondary syphilis or both? ( Helbert, MR; Higgins, SP; Komolafe, AJ; Saxon, CJ, 2014) |
| "To determine incidence and risk factors of nevirapine (NVP)-associated severe hepatitis that led to NVP discontinuation among HIV-infected patients with CD4 < 250 cells/microL." | 7.74 | Incidence and risk factors of nevirapine-associated severe hepatitis among HIV-infected patients with CD4 cell counts less than 250 cells/microL. ( Chaovavanich, A; Chimsuntorn, S; Chottanapund, S; Mankatitham, W; Manosuthi, W; Moolasart, V; Sittibusaya, C; Sungkanuparph, S; Tansuphaswadikul, S, 2008) |
| " We describe a detailed case of fulminant hepatitis induced by nevirapine (Viramune) and treated by liver transplantation." | 7.73 | Liver transplantation for fulminant hepatitis related to nevirapine therapy. ( Antonini, T; Buyse, S; Castaing, D; Duclos-Vallée, JC; Ichai, P; Samuel, D; Sebagh, M; Vibert, E, 2006) |
| "At the defined period, 306 patients started a nevirapine-containing regimen, of whom eight developed an acute hepatitis (2." | 7.72 | Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment. ( Beijnen, JH; de Maat, MM; Mairuhu, AT; Mulder, JW; ter Heine, R; van Gorp, EC, 2003) |
| "We report a case in which an HIV-positive man developed general malaise, skin rash and biochemical hepatitis within days of starting a nevirapine-based antiretroviral treatment regimen." | 3.80 | Rash and hepatitis within days of starting a new antiretroviral regimen: nevirapine hypersensitivity, secondary syphilis or both? ( Helbert, MR; Higgins, SP; Komolafe, AJ; Saxon, CJ, 2014) |
| "To determine incidence and risk factors of nevirapine (NVP)-associated severe hepatitis that led to NVP discontinuation among HIV-infected patients with CD4 < 250 cells/microL." | 3.74 | Incidence and risk factors of nevirapine-associated severe hepatitis among HIV-infected patients with CD4 cell counts less than 250 cells/microL. ( Chaovavanich, A; Chimsuntorn, S; Chottanapund, S; Mankatitham, W; Manosuthi, W; Moolasart, V; Sittibusaya, C; Sungkanuparph, S; Tansuphaswadikul, S, 2008) |
| " We describe a detailed case of fulminant hepatitis induced by nevirapine (Viramune) and treated by liver transplantation." | 3.73 | Liver transplantation for fulminant hepatitis related to nevirapine therapy. ( Antonini, T; Buyse, S; Castaing, D; Duclos-Vallée, JC; Ichai, P; Samuel, D; Sebagh, M; Vibert, E, 2006) |
| "At the defined period, 306 patients started a nevirapine-containing regimen, of whom eight developed an acute hepatitis (2." | 3.72 | Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment. ( Beijnen, JH; de Maat, MM; Mairuhu, AT; Mulder, JW; ter Heine, R; van Gorp, EC, 2003) |
| "The aim of this study was to measure the cumulative incidence of adverse events (AEs) related to nevirapine in patients switched from efavirenz to immediate full-dose nevirapine (FDN)." | 1.35 | Efavirenz replacement by immediate full-dose nevirapine is safe in HIV-1-infected patients in Cambodia. ( Chhneang, V; Fernandez, M; Laureillard, D; Moeung, S; Ngeth, C; Piketty, C; Prak, N; Quillet, C; Riel, V; Song, S, 2008) |
| "Chronic viral hepatitis is common among persons with HIV-1 infection, because of shared modes of transmission, and coinfection results in accelerated liver damage, compared with persons with chronic viral hepatitis alone." | 1.33 | Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. ( Gerber, JG; Wyles, DL, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saxon, CJ | 1 |
| Helbert, MR | 1 |
| Komolafe, AJ | 1 |
| Higgins, SP | 1 |
| Laureillard, D | 1 |
| Prak, N | 1 |
| Fernandez, M | 1 |
| Ngeth, C | 1 |
| Moeung, S | 1 |
| Riel, V | 1 |
| Chhneang, V | 1 |
| Song, S | 1 |
| Quillet, C | 1 |
| Piketty, C | 1 |
| de Maat, MM | 1 |
| ter Heine, R | 1 |
| van Gorp, EC | 1 |
| Mulder, JW | 1 |
| Mairuhu, AT | 1 |
| Beijnen, JH | 1 |
| Wyles, DL | 1 |
| Gerber, JG | 1 |
| Buyse, S | 1 |
| Vibert, E | 1 |
| Sebagh, M | 1 |
| Antonini, T | 1 |
| Ichai, P | 1 |
| Castaing, D | 1 |
| Samuel, D | 1 |
| Duclos-Vallée, JC | 1 |
| Manosuthi, W | 1 |
| Sungkanuparph, S | 1 |
| Tansuphaswadikul, S | 1 |
| Chottanapund, S | 1 |
| Mankatitham, W | 1 |
| Chimsuntorn, S | 1 |
| Sittibusaya, C | 1 |
| Moolasart, V | 1 |
| Chaovavanich, A | 1 |
6 other studies available for nevirapine and Hepatitis
| Article | Year |
|---|---|
Rash and hepatitis within days of starting a new antiretroviral regimen: nevirapine hypersensitivity, secondary syphilis or both?
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Diagnosis, Differential; Exanthema; Hepatitis; HIV Inf | 2014 |
Efavirenz replacement by immediate full-dose nevirapine is safe in HIV-1-infected patients in Cambodia.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cambodia; Cycl | 2008 |
Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment.
Topics: Acute Disease; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Drug Therapy, Combination; Female; He | 2003 |
Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideox | 2005 |
Liver transplantation for fulminant hepatitis related to nevirapine therapy.
Topics: Adult; Anti-HIV Agents; Female; Hepatitis; HIV Infections; HIV-1; Humans; Liver Failure, Acute; Live | 2006 |
Incidence and risk factors of nevirapine-associated severe hepatitis among HIV-infected patients with CD4 cell counts less than 250 cells/microL.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Anti-Retroviral Agents; Aspartate Aminotransferases; C | 2008 |